From vaccines to therapeutics, the emergence of mRNA as a versatile and potent biological tool across the healthcare landscape continues to demand new, innovative ways to scale mRNA manufacturing. To ...
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- TriLink BioTechnologies (TriLink), a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has launched its newest ...
New all-in-one IVT kit can deliver up to 2X more mRNA and up to 85% lower dsRNA compared to other kits on the market through streamlined mRNA synthesis with efficient capping, increased yield, reduced ...
TriLink’s CleanCap technology produces optimal 5′ cap structures with over 95% efficiency, creating a co-transcriptional capping solution that dramatically improves mRNA yield and process time when ...
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...
A research group used a unique 'PureCap' method to produce high purity mRNA vaccines with improved synthesis of proteins that stimulate the immune system and low inflammatory side effects. A research ...
The success of the mRNA-based vaccines against SARS-CoV-2 merely hint at the healthcare implications of mRNA technology. More mRNA-based vaccines are in the works, as are mRNA-based therapeutics for ...
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This 'Purecap' technique ...
A research group from Japan has developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This ‘Purecap’ technique ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results